Public vs. Private: Venture-Backed Companies and the Challenges of Rapid Growth

Date: Thursday, October 16, 2014
Time: 6:00pm-8:45pm
Location: EMC
2421 Mission College Blvd.
Santa Clara, CA 95054



 

 

ACGSV Banner

Public vs. Private: Venture-Backed Companies and the Challenges of Rapid Growth

October 16, 2014 / 6:00PM – 8:45PM / EMC, 2421 Mission College Blvd. Santa Clara, CA 95054

For most of the 20th Century, public markets have proven to be very good at value creation. The US stock market is worth some $17 trillion, and just 10 years of age on your Google IPO purchase would return 1,084%. However, in recent years, more and more companies are opting to stay private longer. While Facebook turned heads for raising venture capital at a valuation of $500M back in 2006, Uber recently recruited Fidelity to back their funding at a massive $18 Billion valuation. This delay of IPO activity not only affects founders, CEOs, and investors, but creates consequences in the economy of the US at large. This panel will examine the changing public and private market conditions, the strategic considerations placed on executives, and how you can successfully navigate this changing climate.

 

OUR DISTINGUISHED PANELISTS

IRWIN FEDERMAN
General Partner, US Venture Partners
Chairman, Mellanox, Inc.
Former Chairmman, SanDisk
Former Vice-Chairman of AMD
Former Chairman, Semiconductor Industry Association

In 1987, in a $442 million stock swap, MMI was merged with Advanced Micro Devices to become the world’s largest integrated circuit manufacturer. Federman was appointed Vice Chairman of AMD. In 1988, he served as Managing Director of investment banking firm Dillon, Read & Co. In 1990, he joined early-stage venture capital firm, U.S. Venture Partners, where he served as General Partner. He previously served on the Boards of Directors of SanDisk, Checkpoint Software Technologies, and Mellanox, Inc.


JEFF KARAN
Founder & Senior Partner
Woodside Capital Partners

Jeff Karan is Founder and Senior Partner of Woodside Capital Partners, a global investment banking firm headquartered in Silicon Valley, which specializes in mergers and acquisitions, capital raising, and strategic partnering for emerging growth companies in the life sciences and technology sectors. He has extensive knowledge of the capital raising and merger and acquisition processes, and advises clients on corporate strategy, strategic partnership, business valuation, and corporate restructuring assignments. He has over 25 years of investment banking and corporate advisory experience, including work at Morgan Stanley and Goldman Sachs prior to founding Woodside Capital Partners.

Mr. Karan is a frequent speaker on investment banking topics internationally. He holds an MBA from Dartmouth’s Amos Tuck School of Business Administration (Tuck Scholar), a BA in Economics from Dartmouth College, and later received an MA on the west coast in Comparative Philosophy and Religion. He is a founding member of the Alliance for Regenerative Medicine in Washington D.C., an Advisory Board member of the Business of Personalized Medicine Summit, a Charter Board member of the non-profit foundation, Opus Novum, and an Advisor to Blue Ocean Sciences, which focuses on scientific collaboration for healthy ocean solutions. Mr. Karan, an avid skier and cyclist, is passionate about philosophy, the history of ideas, poker theory, and global economic analysis.


JOHN RODKIN
Lecturer in Law
Stanford Law School

John Rodkin is a practicing entrepreneur who has been the CEO and co-founder of three venture-backed companies, two of which exited successfully. The first, flyswat, launched the contextual hyperlink advertising market and was acquired by NBC Internet for $120 million. The second, ClickShift, was a search engine marketing company acquired by WebTrends that grew to manage over $100 million in annual client spend. The third was an insurance business that eventually failed. He started all three of these companies while a law student at the University of Chicago. In addition to the venture-backed businesses, John has exited successfully one small LBO and one self funded enterprise. He began his career as an engineer and, during school, spent summers in BigLaw and venture capital. John has BS and M.Eng degrees from MIT and JD and MBA degrees from the University of Chicago, where he was also a lecturer in law for three years.


ANNA BAIRD
CFO
RadiumOne

Anna is the Chief Financial Officer of RadiumOne, providing financial and operational leadership for the company. Prior to joining RadiumOne, Anna was the Chief Financial Officer and Head of Operations at Say Media.
Anna has over 20 years of experience helping technology companies with international expansion and strategic initiatives. She focuses on developing high performing teams and processes that are value add to the business, globally consistent and can scale with growth. Previously, Anna was a Managing Partner at Connor Group providing guidance and leadership to companies working on their initial public offering. Prior to Connor, she was a Senior Vice President at McAfee working with the BOD, CEO and CFO on global strategy, scalability of infrastructure and organizational alignment. She also spent over 17 years at KPMG in Silicon Valley occupying many leadership roles and was the Global Lead Partner on several premier technology companies including Google and Intuit. Anna is a CPA, Six Sigma Green Belt certified and has her BS from CSU Fresno with executive courses from Harvard and Wharton.

 

OUR DISTINGUISHED MODERATOR

DR. TODD MEYERROSE
Co-Founder
PathDrugomics

Dr. Meyerrose is an investor and advisor for seed stage companies in the healthcare sector. He was previously Managing Director at Poliwogg, where he worked to create a public venture fund in healthcare IT. He is a Consulting Associate Professor at Stanford University where he is an advisor to the SPARK program, and co-directs a course on commercialization of biotechnology. Todd is a veteran of several healthcare startups, both as an investor and a founder, most recently working on computational drug discovery with PathDrugomics. His education includes post-doctoral research in the Jaenisch lab at the Whitehead Institute for Biomedical Research, and a Ph.D. in Molecular Cell Biology from Washington University in St. Louis School of Medicine. His academic research is credited in over 16 publications and two books, and he has contributed to successful clinical trials in oncology and gene therapy.